Roles of N(6)-methyladenosine (m(6)A) modifications in gynecologic cancers: mechanisms and therapeutic targeting

Uterine and ovarian cancers are the most common gynecologic cancers. N(6−)methyladenosine (m(6)A), an important internal RNA modification in higher eukaryotes, has recently become a hot topic in epigenetic studies. Numerous studies have revealed that the m(6)A-related regulatory factors regulate the occurrence and metastasis of tumors and drug resistance through various mechanisms. The m(6)A-related regulatory factors can also be used as therapeutic targets and biomarkers for the early diagnosis of cancers, including gynecologic cancers. This review discusses the role of m(6)A in gynecologic cancers and summarizes the recent advancements in m(6)A modification in gynecologic cancers to improve the understanding of the occurrence, diagnosis, treatment, and prognosis of gynecologic cancers.